Ozagrel hydrochloride

Key Product Details

Product Description

Ozagrel hydrochloride is a potent and selective inhibitor of thromboxane (TXA₂) synthetase (IC₅₀ = 4 nM). Does not inhibit prostacyclin (PGI₂) synthetase, cyclooxygenase or PGE₂ isomerase (IC₅₀ > 1 mM). Inhibits platelet aggregation in vitro and arachidonate-induced arterial contraction in vivo.

Product Specifications for Ozagrel hydrochloride

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Ozagrel hydrochloride

The following data is based on the product molecular weight 264.71.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.78 mL	18.89 mL	37.78 mL
5 mM	0.76 mL	3.78 mL	7.56 mL
10 mM	0.38 mL	1.89 mL	3.78 mL
50 mM	0.08 mL	0.38 mL	0.76 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 21 publications citing the usage of this product.

• Naito Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur.J.Pharmacol. 1983 PMID: 6413227
• Shinagawa Participation of thromboxane A₂ in the cough response in guinea-pigs: antitussive effect of ozagrel. Br.J.Pharmacol. 2000 PMID: 10991919
• Hiraku Pharmacological studies on the TXA₂ synthetase inhibitor (E)-3-[p-(1H-imidazol-1ylmethyl)phenyl]-2-propenoic acid (OKY-046). Jpn.J.Pharmacol. 1986 PMID: 3093741

Product Documents for Ozagrel hydrochloride